Physician profile
Brett Opell
NPI 1629173679
$5,023.26
in general payments reported to CMS, 2019-2025
40 companies · $1,023 in 2025
The $1,023 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,107 · 2020: $322 · 2021: $918 · 2022: $452 · 2023: $798 · 2024: $402 · 2025: $1,023.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,223.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $771.10 | 2019-2025 | |
| Boston Scientific Corporation | $519.47 | 2019-2025 | Rezum Generator, Spaceoar System |
| Janssen Biotech, INC. | $385.34 | 2019-2025 | Rybrevant, Carvykti, Erleada |
| Myriad Genetic Laboratories, INC. | $313.40 | 2023 | Myrisk |
| Endo Pharmaceuticals INC. | $276.72 | 2019-2023 | Xiaflex |
| Koelis INC. | $275.43 | 2021-2024 | |
| Coloplast Corp | $228.76 | 2021-2025 | |
| Neotract INC. | $194.80 | 2019-2020 | |
| Palette Life Sciences, INC. | $167.78 | 2021 | |
| Urogen Pharma, INC. | $159.11 | 2023-2025 | Jelmyto |
| Pfizer INC. | $143.31 | 2019-2020 | |
| Axonics, INC. | $129.59 | 2023 | Axonics, Bulkamid |
| Progenics Pharmaceuticals, INC. | $124.98 | 2025 | |
| Clarus Therapeutics INC. | $124.35 | 2021 | |
| Blue Earth Diagnostics | $123.53 | 2019 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $121.84 | 2025 | |
| Ferring Pharmaceuticals INC. | $118.13 | 2019-2024 | Adstiladrin |
| Procept Biorobotics Corporation | $115.23 | 2019-2020 | |
| Abbvie INC. | $100.04 | 2019-2021 | |
| 180 Medical, INC. | $77.05 | 2020-2021 | |
| Astellas Pharma US INC | $73.99 | 2019-2020 | |
| Tolmar Pharmaceuticals, INC. | $56.07 | 2019-2021 | |
| Endo USA, INC. | $48.38 | 2025 | Xiaflex, Aveed |
| Myovant Sciences INC. | $41.85 | 2021 | |
| Medtronic USA, INC. | $32.52 | 2019 | |
| Acerus Pharmaceuticals Corporation | $26.87 | 2020-2021 | |
| Metuchen Pharmaceuticals | $26.60 | 2019 | |
| Teleflex LLC | $26.44 | 2025 | Urolift |
| Laborie Medical Technologies Corp. | $25.84 | 2025 | |
| Aytu Biopharma, INC. | $22.52 | 2019 | |
| Olympus America INC. | $22.12 | 2021 | |
| Dendreon Pharmaceuticals LLC | $21.75 | 2019 | |
| Ethicon US, LLC | $19.20 | 2019 | |
| Antares Pharma, INC. | $18.25 | 2021 | |
| Verity Pharmaceuticals INC. | $17.59 | 2021 | |
| Royal Biologics, INC. | $16.48 | 2020 | |
| Emd Serono, INC. | $15.00 | 2019 | |
| Merck Sharp & Dohme LLC | $14.92 | 2021 | |
| Urovant Sciences INC | $14.47 | 2021 | |
| Amgen INC. | $12.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brett Opell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.